Regulation of mRNA expression encoding chaperone and co-chaperone proteins of the glucocorticoid receptor in peripheral blood: association with depressive symptoms during pregnancy

E. R. Katz1, Z. N. Stowe1,2, D. J. Newport1, M. E. Kelley2, T. W. Pace1, J. F. Cubells3,4, E. B. Binder1,5*

1 Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Atlanta, GA, USA
2 Rollins School of Public Health, Department of Biostatistics and Bioinformatics Atlanta GA, USA
3 Emory University School of Medicine, Department of Obstetrics and Gynecology, Atlanta, GA, USA
4 Emory University School of Medicine, Department of Human Genetics, Atlanta, GA, USA
5 Max Planck Institute of Psychiatry, Munich, Germany

Background. Major depressive disorder during pregnancy associates with potentially detrimental consequences for mother and child. The current study examined peripheral blood gene expression as a potential biomarker for prenatal depressive symptoms.

Method. Maternal RNA from whole blood, plasma and the Beck Depression Inventory were collected longitudinally from preconception through the third trimester of pregnancy in 106 women with a lifetime history of mood or anxiety disorders. The expression of 16 genes in whole blood involved in glucocorticoid receptor (GR) signaling was assessed using real-time polymerase chain reaction. In parallel, plasma concentrations of progesterone, estradiol and cortisol were measured. Finally, we assessed ex vivo GR sensitivity in peripheral blood cells from a subset of 29 women.

Results. mRNA expression of a number of GR-complex regulating genes was up-regulated over pregnancy. Women with depressive symptoms showed significantly smaller increases in mRNA expression of four of these genes – FKBP5, BAG1, NCOA1 and PPID. Ex vivo stimulation assays showed that GR sensitivity diminished with progression of pregnancy and increasing maternal depressive symptoms. Plasma concentrations of gonadal steroids and cortisol did not differ over pregnancy between women with and without clinically relevant depressive symptoms.

Conclusions. The presence of prenatal depressive symptoms appears to be associated with altered regulation of GR sensitivity. Peripheral expression of GR co-chaperone genes may serve as a biomarker for risk of developing depressive symptoms during pregnancy. The presence of such biomarkers, if confirmed, could be utilized in treatment planning for women with a psychiatric history.

Introduction

In 2000, depression was the leading cause of non-fatal disease burden in the world (Üstün et al. 2004) and is projected to remain among the top three causes of burden of disease in coming decades (Mathers & Loncar, 2006). The lifetime risk of major depressive disorder (MDD) is nearly two times higher for women than for men (Kessler et al. 1994) and, within a woman’s lifetime, the childbearing years represent a period of increased vulnerability (Burke et al. 1991). The point prevalence of depression during pregnancy is similar to that during the postpartum period, with estimates ranging from 8 to 13% (O’Hara et al. 1990; Cox et al. 1993; Evans et al. 2001; Gavin et al. 2005).

As in non-puerperal MDD, psychosocial stressors clearly associate with an increased risk for perinatal depressive symptoms (Paykel et al. 1980; O’Hara et al. 1983, 1984; Gotlib et al. 1991; Brett & Barfield, 2008). While there are several studies of biological factors associated with postpartum depression (Wisner & Stowe, 1997; Bloch et al. 2003; Yonkers et al. 2011), fewer have addressed biomarkers for depression during pregnancy (Oretti et al. 1997; Bunevicius et al. 2009;
modulates the downstream gene expression in target cells elicited by cortisol binding at the GR. Because the expression of some of these GR-regulating molecules can be induced by glucocorticoids and gonadal steroids (Tang et al. 1995; Kumar et al. 2001; Hubler et al. 2003; Hubler & Scammell, 2004), the levels of which are rising over the course of pregnancy, they are, on the one hand, prime candidates as mediators of gestational changes in GR-sensitivity and, on the other hand, putative molecular markers for depression-related changes in steroid receptor function.

Interestingly, the profile of increased cortisol release and relative GR insensitivity during pregnancy resembles the endocrine abnormalities often observed in non-puerperal MDD (Holsboer, 2000; Pariente & Miller, 2001). The aims of the current study were to test whether: (i) whole blood gene expression of chaperones and co-chaperones of the GR or related transcription factors changes during pregnancy and whether such changes associate with maternal depressive symptoms; (ii) whether differences in plasma levels of cortisol or sex steroids accompany either depression-associated differences in gene expression or differences in GR sensitivity. The study focused on a clinical sample of women at high risk for depressive symptoms during pregnancy secondary to a lifetime history of mood or anxiety disorders.

Method

Subject ascertainment and assessment

Women with a lifetime history of a mood and/or anxiety disorder, recruited through self-referral or referral from community obstetrical or psychiatric practices, were enrolled in a longitudinal investigation at the Emory Women’s Mental Health Program supported by the Specialized Center for Research on Sex and Gender Effects (P50 MH 68036). Inclusion criteria for this mRNA expression sub-study were: (1) enrollment between March 2005 and December 2007; (2) lifetime history of an Axis I mood or anxiety disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV; First et al. 1995); (3) taking no psychotropic medication for at least 2 weeks before a minimum of one blood draw; (4) preconception or currently pregnant (<24 weeks gestation based on last menstrual period); (5) able to give written informed consent for research participation as approved by the Emory University Institutional Review Board. Women were excluded if they: (1) were actively suicidal; (2) exhibited current psychotic symptoms; (3) were severely anemic; (4) had a positive urine drug screen; (5) had an abnormal thyroid stimulating hormone; or (6) were abusing...
alcohol or drugs in the past 12 months. For ex-vivo GR sensitivity measures, women treated with a selective serotonin reuptake inhibitor at a stable dose for at least 2 weeks were also included.

A DSM-IV primary diagnosis and co-morbid diagnoses were established at enrollment using the Structured Clinical Interview (First et al. 1995). The severity of depressive symptoms was assessed at each visit using the Beck Depression Inventory (BDI) (Beck et al. 1961). Consistent with our recent report establishing a BDI cut-point to identify patients likely to fulfill DSM-IV criteria for depression during pregnancy (Ji et al. 2010), we utilized a BDI cut-point of ≥15 in the current study.

**Biological samples**

Samples were collected by standard venepuncture and frozen at −20°C until RNA extraction or −80°C until plasma hormone assay. Fresh blood from a group of 29 women was processed immediately after collection for use in the ex vivo bioassay of GR sensitivity.

**RNA extraction and quantification by real-time polymerase chain reaction**

Blood for RNA extraction was collected directly into either PAXgene blood tubes (PreAnalytix, Switzerland) or Tempus blood RNA tubes (Applied Biosystems Inc., USA). RNA extraction was performed using a modified protocol (available upon request) from the Versagene RNA Purification Kit for Cell Culture in a 96-well format (Gentra Systems Inc., USA).

Total RNA was reverse transcribed according to the manufacturer’s protocol using the cDNA Archive kit (Applied Biosystems Inc.) and the resulting cDNA was quantified using the Quant-it Picogreen Kit (Invitrogen, USA). Each sample was diluted to 0.5 ng/µl and plated in duplicate into 384-well plates for assay on a 7900HT real-time polymerase chain reaction (RT-PCR) system using Taqman human gene expression assays (Applied Biosystems Inc.) for transcripts listed in Table 1. The assay IDs used in this study were: BAG1-Hs00185390_m1; CDC37L1-Hs00215561_m1; FKBP4-Hs00427038_g1; FKB5-Hs00188025_m1; NCOA1-Hs00186661_m1; HSP90AA1-Hs00743767_sH; HSPA1A; HSPA1B-Hs00271229_s1; NCOR1-Hs01094540_m1; NR3C1-Hs00230818_m1; PPID-Hs00234593_m1; PPP5C-Hs00196577_m1; PTGES3-Hs00832847_gH; RPLP0-Hs009999902_m1; ST13-Hs00832556_sH; STIP1-Hs00428979_m1; STUB1-Hs00195300_m1; TFRC-Hs99999911_m1. For quality control, concordance of duplicates was assessed and samples with a crossing threshold (CT) >35 and S.D. >0.25 CTs apart in each duplicate pair were excluded from further analyses.

Raw fluorescence data were used to estimate the polymerase chain reaction (PCR) efficiency for each reaction using the LinRegPCR program (Ramakers et al. 2009).

<table>
<thead>
<tr>
<th>Gene ID and common synonyms</th>
<th>Gene name</th>
<th>Involvement in GR processing</th>
</tr>
</thead>
<tbody>
<tr>
<td>NR3C1</td>
<td>Glucocorticoid receptor</td>
<td>Receptor protein</td>
</tr>
<tr>
<td>HSP70</td>
<td>Heat shock 70 kDa protein 1</td>
<td>Folding</td>
</tr>
<tr>
<td>ST13 (Hip)</td>
<td>Suppression of tumorigenicity 13/HSP70 interacting protein</td>
<td>Folding</td>
</tr>
<tr>
<td>STIP1 (Hop, p60)</td>
<td>Stress-induced-phosphoprotein 1 (Hsp70/Hsp90 organizing protein)</td>
<td>Maturation</td>
</tr>
<tr>
<td>HSP90</td>
<td>Heat shock 90 kDa protein 1, alpha</td>
<td>Maturation, DNA binding</td>
</tr>
<tr>
<td>P23 (TEBP)</td>
<td>Unactive progesterone receptor, 23 kDa</td>
<td>Maturation</td>
</tr>
<tr>
<td>FKB5 (FKBP51)</td>
<td>FK506 binding protein 5</td>
<td>Maturation</td>
</tr>
<tr>
<td>PPP5C (PP5)</td>
<td>Protein phosphatase 5, catalytic subunit</td>
<td>Maturation</td>
</tr>
<tr>
<td>CDC37L1 (HARC)</td>
<td>Cell division cycle 37 homolog-like 1/Hsp90-associating relative of Cdc37</td>
<td>Maturation</td>
</tr>
<tr>
<td>PPIA (CyplA)</td>
<td>Peptidylprolyl isomerase A (cyclophilin A)</td>
<td>Maturation</td>
</tr>
<tr>
<td>PPID (CyplD)</td>
<td>Peptidylprolyl isomerase D (cyclophilin D)</td>
<td>Maturation</td>
</tr>
<tr>
<td>FKB4 (FKBP52)</td>
<td>FK506 binding protein 4, 59 kDa</td>
<td>Trafficking</td>
</tr>
<tr>
<td>BAG1 (RAP 46)</td>
<td>BCL2-associated athanogene</td>
<td>Folding, DNA binding, degradation</td>
</tr>
<tr>
<td>STUB1 (CHIP)</td>
<td>STIP1 homology and U-Box containing protein 1</td>
<td>Degradation</td>
</tr>
<tr>
<td>NCOA1</td>
<td>Nuclear receptor corepressor 1</td>
<td>DNA binding</td>
</tr>
<tr>
<td>NCOA1 (SRC-1)</td>
<td>Nuclear receptor coactivator 1</td>
<td>DNA binding</td>
</tr>
</tbody>
</table>

Table 1. Transcripts of interest including their role in glucocorticoid receptor (GR) processing
et al, 2003). Mean assay-specific efficiencies were then used in conjunction with the CT values to calculate relative ratios of the target mRNA to that of the endogenous control gene, RPLP0 (Ramakers et al. 2003; Karlen et al. 2007). CT values were calculated using default settings within the RQ Manager version 1.2 software (Applied Biosystems Inc.). We observed a systematic difference in the magnitude but not the direction of gene-expression regulation over pregnancy in the positive control gene (TFRC) between samples collected in PAXgene versus Tempus tubes. To address this bias, we performed a Z score transformation on the raw data for each type of tube. This type of correction is commonly utilized in studies of gene expression data derived from different batches of extracted RNA or different assay platforms (Cheadle et al. 2003). All values were normalized first to the endogenous control gene, RPLP0, and subsequently normalized to the mean of the preconception values.

Selection of endogenous and positive control genes

In order to identify an appropriate endogenous control gene for the RT-PCR assays, we pooled four normalized cDNA samples each from women who were preconception, at 12 weeks, 21 weeks, 36 weeks gestation and between 0 and 8 weeks postpartum. These samples were run on the Taqman Human Endogenous Control Array (Applied Biosystems Inc.). The array contained the genes: ACTB; AVPR1B; B2M; CANX; CCT7; CPB1; GAPD; GUSB; HPRT1; HSPCB; JUNB; KCNMB1; LDHB; PFDN5; PGK1; PLN; PPIA; PLTP; RPLP0; TAP1; TBP; TFRC; TGB1. The CT values for RPLP0 were the least variable across all time points, <0.15 CT difference. Therefore, this transcript was chosen as the endogenous control gene for this study. As expected based on prior studies, TFRC, which encodes the transferrin receptor, was highly regulated during pregnancy (Akesson et al. 1998; Choi et al. 2000) and was thus chosen as a positive-control transcript for pregnancy-dependent regulation.

Hormone measures

Plasma concentrations of cortisol, estradiol and progesterone were measured using direct radioimmunoassay kits from Diagnostic Systems Laboratories (USA). The sensitivity of these kits were 0.11 pg/dL, 4.7 pg/mL and 0.12 ng/mL and the inter-assay correlation of variation was 11.1%, 6.9% and 4.5% for cortisol, estradiol and progesterone, respectively.

GR Sensitivity

To assess GR sensitivity, we used an ex vivo assay that estimates the degree of suppression of interleukin-6 (IL-6) secretion by the synthetic glucocorticoid, dexamethasone, in peripheral leukocytes, as described by DeRijk et al. (1996) and modified by Miller et al. (2005). Altogether, 8 ml of blood were drawn into lithium-heparin anti-coagulating vacutainer tubes (Becton-Dickinson, USA) and diluted 10:1 with 0.9% saline solution within 60 min of collection. In total, 800 μl of the diluted blood were added to 100 μl of lipopolysaccharide (LPS; Sigma Chemical, USA) and 100 μl of dexamethasone (Sigma Chemical) in each of six wells in a 24-well flat bottom plate. The final concentration of LPS was 100 ng/mL, while the final concentrations of dexamethasone were 0, 1, 10, 100, 1000 or 10 000 nM. Following a 6-h incubation at 37°C in an atmosphere containing 5% CO2, the plate was centrifuged for 10 min at 1000 g. The plasma was then aspirated and stored at −20°C until assay of IL-6 using a commercial ELISA kit (Biosource Diagnostics, Belgium). The sensitivity of the ELISA kit was 2.9%. Using Sigmaplot 10.0 (USA), a dose-response curve was determined for each sample from the ELISA results and the concentration of dexamethasone necessary to suppress 50% of the IL-6 expression (IC50) was calculated.

Data analysis

Gene expression analyses

To identify potential confounders, the following parameters were tested for associations with whole blood gene expression for all transcripts: age; years of education; marital status; race; gravidity; parity; primary maternal DSM-IV diagnosis. Primary diagnosis was significantly associated with mRNA levels for several genes of interest and thus entered into the full model.

To assess the impact of pregnancy on gene expression, we examined gene expression changes in samples of non-depressed women using a SAS version 9.1 (USA) mixed model analysis accounting for repeated measures and missing time points within subjects. For each gene, the dependent variable was the Z score for mRNA expression ratio. Predictors included trimester (preconception, first trimester, second trimester, third trimester) and DSM-IV primary diagnosis. Results for each subject were averaged within a trimester if more than one sample was collected during this time-frame.

The association of maternal depression with gene expression during pregnancy was tested using a mixed model analysis with maternal depression (dichotomous variable determined by BDI cut-point), trimester and maternal DSM-IV primary diagnosis as predictors.
Plasma hormone concentrations

Changes in plasma hormone levels of estradiol, progesterone and cortisol over pregnancy and in association with maternal depression were analyzed using a general linear model. We included estimated gestational age in weeks as well as time of day of the blood draw [coded as a trichotomous variable – morning (09:00–11:00 hours), noon and early afternoon (11:00–16:00 hours) and late afternoon (16:00–19:00 hours)] but none of the other above-mentioned covariates as they failed to demonstrate an association with the hormone measures.

GR sensitivity

Analyses of the effects of pregnancy and depression on GR sensitivity were performed using SPSS version 15 (USA) with IC$_{50}$ measures as the outcome using general linear models and partial correlation analysis. To increase the resolution of this analysis, gestational age was entered as gestational days and not grouped into trimesters.

All statistical tests were two-tailed with $\alpha = 0.05$. No correction for multiple testing was applied. It has to be noted, however, that the expression levels across all samples of the 16 GR-related transcripts were all significantly correlated (Pearson’s $R$ ranging from 0.31 to 0.83) – so that methods for correction assuming independent tests would be overly conservative.

Results

Patient demographics, clinical characteristics and biological samples

Altogether, 106 women, from whom 137 mRNA samples were collected, qualified for inclusion. Table 2 summarizes the demographic and clinical profile of the participants. In total, 46 (46.2%) women contributed two or more mRNA samples; 33.7% of the mRNA samples were collected when women were depressed. The mean (S.D.) BDI score for samples collected when women were non-depressed and depressed, respectively, was 6.7 (4.4) and 22.6 (6.2) for preconception, 8.8 (4.4) and 28.0 (8.7) for the first trimester, 7.7 (4.4) and 23.4 (5.8) for the second trimester and 8.4 (4.0) and 24.1 (7.6) for the third trimester. A total of 20 samples were collected preconception, 16 during the first trimester, 46 during the second trimester and 55 during the third trimester. Plasma for hormonal assay was collected from 61 of these subjects at the same time point as the mRNA ($n=74$ samples, 10 preconception, five in the first trimester, 28 in the second trimester and 29 in the third trimester). Of the 29 women participating in the ex-vivo GR sensitivity assay study, 11 were not part of the 106 women of the gene expression study. In addition, samples were taken later in pregnancy for this study in some of the 18 women participating in the gene expression studies, so that the GR sensitivity assays were performed when some women initially off medication were now treated.

Gene expression changes during pregnancy in non-medicated, non-depressed women

Results of the mixed model analysis of pregnancy-related gene expression, limited to samples collected
Non-medicated, depressed and non-depressed women during pregnancy

The mixed model analysis of the impact of both maternal depression and pregnancy on gene expression demonstrated no significant interactions between trimester and depression status for any of the genes, enabling interpretation of marginal main effects. We observed a significant main effect of depression on gene expression for BAG1 ($F = 4.51, df = 1.23; p = 0.04$), FKB5 ($F = 4.63, df = 1.23; p = 0.04$), NCOAI ($F = 4.43, df = 1.22; p = 0.05$) and PPID ($F = 6.36, df = 1.23; p = 0.02$) as well as a significant trimester effect for these four genes (see Fig. 2). While gene expression across pregnancy was up-regulated for these genes, the magnitude of the up-regulation was diminished when women were depressed relative to when they were not depressed.

Plasma concentrations of cortisol, estradiol and progesterone in pregnancy in depressed and non-depressed women

Mixed model analyses demonstrated a significant effect of trimester on estrogen ($F = 28.8; df = 3.7; p < 0.001$), progesterone ($F = 9.37; df = 3.7; p < 0.01$) and total cortisol levels ($F = 11.2; df = 3.7; p < 0.005$), but no main effect of depression nor any interaction between trimester and depression (see Fig. 3). To control for potential effects of different estimated gestational ages as well as the time of day of the blood draw, we added these two variables into the model. As expected, estimated gestational age had a significant effect on all three hormones ($p = 0.024$ for cortisol, $p = 0.003$ for estradiol and $p = 0.005$ for progesterone), but the addition of this covariate did not change the absence of significance of the main depression effect as well as the interaction between trimester and depression. The time of day of the blood draw did not have a significant effect on hormone measures across pregnancy.

GR sensitivity during pregnancy

To test whether the observed depression-related gene expression differences are associated with differences in GR function, we examined GR sensitivity using an *ex vivo* assay in a group of 29 women. We first investigated the changes of GR sensitivity across pregnancy in 23 women without clinically relevant depressive symptoms [BDI mean (s.d.) = 6.0 (4.5)].
Using a partial correlation between IC\textsubscript{50} values and estimated gestational day and correcting for medication status and DSM-IV diagnosis, we observed a significant positive correlation with IC\textsubscript{50} and estimated gestational age—i.e. GR sensitivity declined as pregnancy progressed (Fig. 4\textit{a}; \( r=0.474, \text{df}=19, p=0.030 \)). We then examined whether we would observe an association of IC\textsubscript{50} levels with depression severity and correlated IC\textsubscript{50} values with the total score of the BDI in the whole group of women (\( n=29 \)), controlling for medication, DSM-IV diagnosis and estimated gestational age. We observed a significant positive correlation between BDI scores and IC\textsubscript{50} (\( r=0.422, \text{df}=22, p=0.032 \)), supporting an additional decline of GR sensitivity with increasing depressive symptoms over and above that due to pregnancy (Fig. 4\textit{b}).

We observed no difference in IC\textsubscript{50} between the 12 women off and the 17 women on medication (\( t=-0.174, \text{df}=27, p=0.83 \)).

**Discussion**

In this study, we present data showing up-regulation of expression of specific peripheral blood mRNAs encoding chaperone, co-chaperone and transcription factor proteins critical for GR function across pregnancy in women with a history of mood or anxiety disorders. These changes are paralleled by decreases of GR sensitivity in peripheral blood cells over pregnancy, confirming the results of investigations performed over two decades ago of GR sensitivity in pregnancy using the DST (Greenwood & Parker, 1984; Smith \textit{et al.} 1987). These findings need to be replicated in a healthy control group to extrapolate results for euthymic, unmedicated patients to the general population. It also has to be noted that no correction for multiple testing has been applied, underscoring the exploratory nature of the study.

Our data further suggest that maternal depression diminishes the pregnancy-related up-regulation of
gene expression for BAG1, FKBP5, PPID and NCOA1. Consistent with some (Zonana & Gorman, 2005; Brummelte & Galea, 2009; King et al. 2010) but not all (Evans et al. 2008; Field et al. 2008; O’Keane et al. 2010) studies, our data did not demonstrate any impact of maternal depression or anxiety during pregnancy on circulating concentrations of cortisol or gonadal steroids. However, because our measures of plasma hormone levels only occurred at one time point during the day and represent total but not free hormone levels, we cannot exclude the possibility that differences in overall diurnal secretion of hormones or differences in free hormone levels contributed to the observed findings. Nonetheless, most studies report a higher cortisol level with depression in pregnancy (Evans et al. 2008; Field et al. 2008; O’Keane et al. 2010), which should, at least for FKBP5, be associated with higher and not lower gene expression levels (Jaaskelainen et al. 2011).

Differences in chaperone and co-chaperone expression profiles could also be due to changes in the composition of the white blood cell subpopulations, which we cannot differentiate as we were using whole blood to assess both mRNA expression levels and GR function. However, data from a set of 45 non-pregnant individuals (69% women) indicate that transcript levels of the genes differentially regulated in depressed compared with non-depressed women as well as over pregnancy are not significantly correlated with the relative proportions of leukocyte subtypes (data not shown).

To minimize the effects of antidepressant therapy, gene expression and hormone assay analyses were conducted in samples from patients who denied taking psychotropic drugs for at least 2 weeks. We cannot exclude the possibility that drugs with longer half-lives (e.g. fluoxetine) or residual effects of psychotropic drugs could still influence gene expression. Further studies in drug-free women will be necessary to address whether any of the observed changes could be related to enduring effects of antidepressant exposure. The current study design also did not allow us to use transcription profiles for prediction of future depression, as most women received antidepressant medication at one point during pregnancy. While primary psychiatric diagnosis showed main effects on select transcripts, this variable did not influence the association of expression levels with trimester or maternal depressive symptoms. While psychiatric diagnosis is not likely a major confounder of the present analyses, the significant main effects are interesting and need to be investigated in larger samples that include healthy volunteers.

Interestingly, the relative decrease in gene expression of specific transcripts in association with

![Graph](https://example.com/graph1.png)

**Fig. 3.** Plasma hormone levels over pregnancy in depressed versus non-depressed non-medicated high risk patients. The first trimester group only included $n = 3$ and $n = 2$ for non-depressed and depressed and are not represented in the graph. Group sizes: preconception: $n = 5/5$, second trimester: $n = 19/11$ and third trimester: $n = 17/12$. Data are presented as in box-plot showing the median and interquartile range as well as outliers. Hormone plasma concentrations are shown in ng/ml for progesterone, pg/ml for estradiol and $\mu$g/dl for cortisol.
depression during pregnancy, presented in this paper, parallels previously published results for post-partum depression using gene expression microarrays (Segman et al. 2010). In the latter study, women developing persisting postpartum depression exhibited lower levels of a number of transcripts in whole blood sampled directly after delivery. Decreased gene expression with depressive symptoms in the peripartum period might thus reflect more general molecular mechanisms altering the dynamics of gene expression changes, such as global changes in transcription factor signaling or epigenetic modifications. Differences in epigenetic measures have been observed in peripheral blood cells of depressed patients (Iga et al. 2007).

**GR sensitivity in peripartum depression**

It has been hypothesized that decreased GR sensitivity during pregnancy protects from potential adverse sequelae of rapidly increasing plasma cortisol levels, such as a premature escalation in the placental release of CRH, which might alter the timing of delivery.

---

Fig. 4. Glucorticoid receptor sensitivity in pregnancy and with peripartum depression. (a) Shows the correlation between IC₅₀ (mol) of the dexamethasone suppression of lipopolysaccharide-stimulated interleukin-6 release and estimated gestational age in days in euthymic women (n = 23). The line shows the linear trend for this correlation in non-depressed women, r = 0.474, r² = 0.179, p < 0.05; (b) shows correlation between IC₅₀ and Beck Depression Inventory (BDI) scores in all 29 women. The line shows the linear trend for this correlation, r = 0.422, r² = 0.132, p < 0.05, corrected for gestational age and SCID diagnosis. In both (a) and (b), ○ represent data from patients off antidepressant medication and ● represent data from patients on antidepressant medication.
(McLean et al. 1995; Smith & Nicholson, 2007). In addition to confirming that GR sensitivity decreases during pregnancy, our data suggest that this change in GR sensitivity is paralleled by an up-regulation of several chaperone and co-chaperone genes regulating GR function. This regulation could be the consequence of the activation of sex-steroid response elements in these genes with rising hormone levels throughout pregnancy. Functional progesterone response elements have been described for FKBP5, for example (Hubler & Scammell, 2004; U et al. 2004). Regulation of these transcripts might, in fact, constitute a read-out of pregnancy-related GR sensitivity changes.

Data from the ex vivo GR function assay suggest that, in addition to pregnancy, increased severity of depressive symptoms is associated with a further decrease in GR sensitivity. These data parallel what is seen in non-gravid depression, in which decreases in GR sensitivity are observed in a subset of patients with major depression (Holsboer, 2000; Pariante & Miller, 2001). The current results, obtained from the study of peripheral blood cells, preclude direct extrapolation of these data to the function of the GR in other tissues, such as the brain. However, the brain and the immune system share many signaling pathways that both respond to GR-activation and several studies support the concept that changes in GR signaling in immune cells often parallels similar regulation of central GR function (Lowy et al. 1984, 1988; Holsboer & Barden, 1996; Pariante & Miller, 2001; Pariante, 2004).

Differences in GR sensitivity could also be related to placental dysfunction and associated changes in placental CRH release, which have been shown to impact obstetric outcomes. In our dataset, we did not observe a correlation of the expression levels of FKBP5, NCOA1, PPID or BAG1 in the third trimester on estimated gestational age at delivery, baby weight, APGAR at 1 and 5 min after delivery of days spent in the neonatal intensive care unit (data not shown, n=52). We therefore conclude that the observed associations of depression and peripheral gene expression are not strongly related to placental dysfunction.

Chaperone and co-chaperone mRNA transcription and GR function – cause or consequence?

The investigated chaperone and co-chaperone molecules play a dual role in GR signaling. While these molecules regulate steroid receptor function, their transcription is, in turn, regulated by activation of these receptors, forming a feedback system. Previous studies have shown that cortisol, estradiol and progesterone exposure alter the expression of a number of our genes of interest in vitro (Tang et al. 1995; Kumar et al. 2001; Hubler & Scammell, 2004). This steroid-dependent regulation of gene transcription is likely mediated via the interaction of these receptors with hormone response elements (HREs) located in the target genes. FKBP5, for example, contains functional HREs responsive to cortisol, progesterone and androgens (Hubler & Scammell, 2004; Paakinaho et al. 2010). The observed parallel increases of steroid-regulated transcripts with rising steroid hormone levels during pregnancy suggest that transcriptional regulation via steroid hormone receptor activation might represent a molecular mechanism for the observed up-regulation of gene transcripts during pregnancy.

Differences in mRNA levels between depressed and non-depressed women could thus be the consequence of differences in hormone receptor sensitivity or hormone receptor number. We have clearly observed differences in GR-sensitivity over pregnancy, as well as with depressive symptoms. However, we also observe an up-regulation of NR3C1 (the gene encoding the GR) mRNA, during pregnancy, but no mRNA differences with depressive symptoms. So while receptor number might play a role in pregnancy-related gene expression changes, this seems less likely for depression-related differences. This issue needs further confirmation using assays directly measuring GR-protein. We also cannot rule out additional contributions of differences in sex-steroid receptors or potential differences in epigenetic mechanisms as a source for this effect.

As stated above, the investigated chaperones and co-chaperones are not only regulated by steroid receptor activation, but, in turn, influence the function of these receptors. If up-regulation of chaperone and co-chaperone gene expression levels does contribute to decreases in GR sensitivity, one would expect that depressed women with less up-regulation display higher GR sensitivity, which is not the case in our sample. In addition, BAG1, FKBP5, NCOA1 and PPID – all differentially regulated with depressive symptoms – have proposed opposite roles in GR signaling (negative for BAG1 and FKBP5 and positive for NCOA1 and PPID) (Bimston et al. 1998; Kullmann et al. 1998; Kimmins & MacRae, 2000; Kurihara et al. 2000; Morishima et al. 2000; Schneikert et al. 2000; Davies et al. 2002; Ratajczak et al. 2003; Odunuga et al. 2004; Meijer et al. 2005). It is thus unlikely that their transcriptional levels directly relate to GR function in a simple linear manner. Their decreased up-regulation is most likely a marker of altered GR (or other steroid hormone receptor) sensitivity in pregnant women with depression. In fact, FKBP5 mRNA regulation has been proposed as a marker for GR activation and sensitivity in peripheral blood cells (Vermeer et al. 2004; Jaaskelainen et al. 2011). These GR chaperone
and co-chaperones, especially FKBP5, have a dual role and (1) moderate GR activity and (2) their transcriptional regulation can serve as a molecular read-out of GR activation and sensitivity. Our data provide evidence for these genes as markers for GR-sensitivity, but do not allow us to infer whether their expression changes are causally involved in depression-related GR resistance.

Conclusions

Our data suggest that depressive symptoms during pregnancy are associated with differences in GR chaperone gene expression in whole blood. These differences in expression levels could be a molecular marker of GR-sensitivity, which is decreased in depression during pregnancy. Individual differences in sensitivity to glucocorticoids may contribute to differences in long-term outcomes associated with GR-mediated signaling, including a number of adverse fetal outcomes (Robinson et al. 1988; Goland et al. 1993; Karalis et al. 1996; Clark, 1998; Patel & Challis, 2002, Meaney et al. 2007). GR chaperone gene expression over pregnancy may serve as a marker for these changes in GR sensitivity in women at risk for depressive symptoms and may be of value in treatment planning for high-risk populations.

Acknowledgments

This work was supported by a Specialized Center for Research to Stowe (P50 MH 68036), a Pfizer Scholars Grant in Clinical Psychiatry (to Binder), the Doris Duke Charitable foundation (Career development award to Binder) and R21 MH076024–01 to Binder.

Declaration of Interest

Dr Newport has received research support from Eli Lilly, GSK, Janssen and Wyeth as well as NARSAD and NIH, and speaker’s honoraria from Astra-Zeneca, Eli Lilly, GSK, and Pfizer. Dr Stowe has received research support from GSK, NIH and Wyeth, served on advisory boards for Wyeth, BMS and GSK and received speakers’ honoraria from Eli Lilly, GSK, Pfizer and Wyeth. Dr Cubells has received grant support from NIDA, NIMH, NINDS, NARSAD, Roche and Schering-Plough. Dr Binder receives grant support from NIMH, The Behrens-Weise Foundation and PharmaNeuroBoost.

References


Peripheral blood gene expression in peripartum depression

955


